本文仅供中国大陆地区执业的医学药学专业人士参考,如您非前述专业人士,请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
*此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场
审批编码:PP-IX-CN-4741
审批日期:2024 年 10 月 9 日
内容策划:郭青青
项目审核:曹欢
题图来源:礼来提供
参考文献:
[1]Smolen JS, et al. Ann Rheum Dis 2023;82:3-18.
[2]Alten R, et al. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients[J]. Rheumatol Ther. 2023, 10(6):1575-1595.
[3]Emery P, et al.Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis. J Rheumatol. 2020 Apr;47(4):493-501.
[4] Neovius M, et al.Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015 Feb;74(2):354-60.
[5]Barbulescu A, et al. Rheumatology 2022;61(10):3952–62.
[6]耿研, 谢希, 王昱, 等. 类风湿关节炎诊疗规范 [J] . 中华内科杂志, 2022, 61(1) : 51-59.
[7]Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15.
[8]巴瑞替尼片说明书.
[9]Taylor PC, et al.. Ann Rheum Dis. 2022 Mar;81(3):335-343.
点击「阅读原文」报名会议,收开播提醒~